Trial Profile
A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Pharmacodynamics; Therapeutic Use
- 02 Apr 2018 According to results of a combined analysis of the pilot (NCT00780104; n=15) and subsequent phase II (NCT01184898; n=36) study published in the Investigational New Drugs Journal, secondary endpoints for both studies included assessment of safety, overall survival and incidence of subsequent allogeneic transplantation.
- 02 Apr 2018 Results of a combined analysis of the pilot (NCT00780104; n=15) and subsequent phase II (NCT01184898; n=36) study assessing the association between mTORC1 target inhibition in leukemic blasts and clinical response to a regimen combining sirolimus and MEC chemotherapy, published in the Investigational New Drugs Journal.
- 19 Oct 2016 Status changed from active, no longer recruiting to completed.